{"id":10036,"date":"2025-06-02T19:05:44","date_gmt":"2025-06-02T19:05:44","guid":{"rendered":"https:\/\/csiag.de\/?p=10036"},"modified":"2025-06-03T20:37:17","modified_gmt":"2025-06-03T20:37:17","slug":"lnpn-myrkyllisyys-riippuen-tappiketjun-pituudesta","status":"publish","type":"post","link":"https:\/\/csiag.de\/fi\/blog\/2025\/06\/02\/toxizitaet-der-lnp-in-abhaengigkeit-der-laenge-der-peg-kette\/","title":{"rendered":"LNP:n myrkyllisyys PEG-ketjun pituudesta riippuen"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Sis\u00e4llysluettelo<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.de\/fi\/blog\/2025\/06\/02\/toxizitaet-der-lnp-in-abhaengigkeit-der-laenge-der-peg-kette\/#Welche_LNPs_wurden_verwendet\" >Mit\u00e4 LNP:t\u00e4 k\u00e4ytettiin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.de\/fi\/blog\/2025\/06\/02\/toxizitaet-der-lnp-in-abhaengigkeit-der-laenge-der-peg-kette\/#Toxizitat_wurde_nicht_durch_Studien_uberpruft\" >Myrkyllisyytt\u00e4 ei ole varmistettu tutkimuksilla.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.de\/fi\/blog\/2025\/06\/02\/toxizitaet-der-lnp-in-abhaengigkeit-der-laenge-der-peg-kette\/#Akkumulation_in_der_Leber\" >Kertyminen maksaan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.de\/fi\/blog\/2025\/06\/02\/toxizitaet-der-lnp-in-abhaengigkeit-der-laenge-der-peg-kette\/#Der_Weg_in_die_Leber_und_die_Lange_der_Kette\" >Polku maksaan ja ketjun pituus<\/a><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Lukuaika<\/span> <span class=\"rt-time\"> 2<\/span> <span class=\"rt-label rt-postfix\">minuuttia<\/span><\/span>\n<p>Mit\u00e4 lyhyempi PEG-ketju (polyetyleeniglykoli) on, sit\u00e4 myrkyllisempi LNP on. BioNTech selitt\u00e4\u00e4 t\u00e4m\u00e4n <a href=\"https:\/\/www.mdpi.com\/2227-9059\/9\/5\/530\" target=\"_blank\" rel=\"noreferrer noopener\">Julkaisu<\/a> \"Non-Immunotherapy Application of LNP-mRNA: Maximising Efficacy and Safety\" (LNP-mRNA:n ei-immunoterapian k\u00e4ytt\u00f6: tehokkuuden ja turvallisuuden maksimointi), 10.05.2021, joskin muotoiltuna - hieman - eri tavalla: \"Maximising Efficacy\".<br>Myrkyllisyys perustuu siihen, ett\u00e4 kaikki kolme ionisoituvaa kationista lipidi\u00e4 eiv\u00e4t ole biologisesti hajoavia, ja niiden v\u00e4ist\u00e4m\u00e4tt\u00f6m\u00e4ll\u00e4 kertymisell\u00e4 elimist\u00f6\u00f6n on sytotoksisia vaikutuksia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Welche_LNPs_wurden_verwendet\"><\/span>Mit\u00e4 LNP:t\u00e4 k\u00e4ytettiin?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><em>Pfizer<\/em> \/ <em>BioNTech<\/em> - BNT162b2 - <a href=\"https:\/\/www.echelon-inc.com\/product\/alc-0315\/\" target=\"_blank\" rel=\"noreferrer noopener\">ALC-0315<\/a> (ionisoituvat) ja <a href=\"https:\/\/www.echelon-inc.com\/product\/alc-0159\/\" target=\"_blank\" rel=\"noreferrer noopener\">ALC-0159<\/a> (PEGyloitu)<br><em>Moderna<\/em> - <a href=\"https:\/\/www.echelon-inc.com\/product\/sm-102\/\" target=\"_blank\" rel=\"noreferrer noopener\">SM-102<\/a> (ionisoituvat) ja <a href=\"https:\/\/www.echelon-inc.com\/product\/dmg-peg-2000\/\" target=\"_blank\" rel=\"noreferrer noopener\">PEG2000-DMG<\/a> (PEGyloitu)<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"562\" src=\"https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-1024x562.png\" alt=\"\" class=\"wp-image-10045\" srcset=\"https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-1024x562.png 1024w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-300x165.png 300w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-768x421.png 768w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-18x10.png 18w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image.png 1456w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<p>Kaikkien edell\u00e4 mainittujen lipidien osalta valmistajat (esim. <a href=\"https:\/\/www.echelon-inc.com\/product\/alc-0315\/#tab-description\" target=\"_blank\" rel=\"noreferrer noopener\">Echelon Biosciences<\/a>) \"... T\u00e4m\u00e4 on reagenssilaatuinen tuote, vain tutkimusk\u00e4ytt\u00f6\u00f6n.\".<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Toxizitat_wurde_nicht_durch_Studien_uberpruft\"><\/span>Myrkyllisyytt\u00e4 ei ole varmistettu tutkimuksilla.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Mukaan <a href=\"https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-2389-06.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Julkaisu<\/a> Australian hallituksen - terveysministeri\u00f6n tammikuun 2021 \"Nonclinical Evaluation Report BNT 162b2 mRNA COVID-19 vaccine COMIRNATY\u2122\" -raportin sivulta 11 on luettavissa: \"Pelk\u00e4n LNP-formulaation tai uusien apuaineiden toksisuutta ei tutkittu erityisesti.\"\"<br>Toisin sanoen edell\u00e4 mainittujen uusien LNP:n apuaineiden k\u00e4yt\u00f6st\u00e4 ja vaikutuksista ei ole tehty toksisuustutkimuksia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akkumulation_in_der_Leber\"><\/span>Kertyminen maksaan<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Monet l\u00e4\u00e4kkeet metaboloituvat osittain tai kokonaan maksassa ja kulkeutuvat verenkiertoon. My\u00f6s edell\u00e4 mainittu apuaine ALC-315 kertyy maksaan, kuten voidaan todeta, kun otetaan huomioon <a href=\"https:\/\/www.judicialwatch.org\/wp-content\/uploads\/2022\/03\/JW-v-HHS-prod-3-02418.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Osittainen vastaus kysymykseen nro 2021-4379.<\/a> tiedonv\u00e4lityksen vapautta koskevan lain (Freedom of Information Act, FOIA) nojalla, joka on valituksen kohteena asiassa Judicial Watch, Inc. v. U.S. Department of Health and Human Services (21-cv-2418), joka on t\u00e4ll\u00e4 hetkell\u00e4 vireill\u00e4 U.S. District Court for the District of Columbia -oikeudenk\u00e4ynniss\u00e4, sivulla 16 466:sta:<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"542\" src=\"https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-3-1024x542.png\" alt=\"\" class=\"wp-image-10054\" srcset=\"https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-3-1024x542.png 1024w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-3-300x159.png 300w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-3-768x407.png 768w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-3-18x10.png 18w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-3.png 1212w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Mainitaan my\u00f6s edell\u00e4 mainitun kertomuksen sivulla 45. <a href=\"https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-2389-06.pdf\" target=\"_blank\" rel=\"noopener\">Raportit<\/a>:<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"55\" src=\"https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-4-1024x55.png\" alt=\"\" class=\"wp-image-10060\" srcset=\"https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-4-1024x55.png 1024w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-4-300x16.png 300w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-4-768x42.png 768w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-4-18x1.png 18w, https:\/\/csiag.de\/wp-content\/uploads\/2025\/06\/image-4.png 1218w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Sivulla 46 esitet\u00e4\u00e4n puhtaasti teoreettisesti oletettu aineenvaihduntareitti, joka perustuu in vitro -kokeisiin, vaikka sit\u00e4 ei ole vahvistettu ihmisill\u00e4.<\/p>\n\n\n\n<p>Vaikka <a href=\"https:\/\/www.statnews.com\/2017\/01\/10\/moderna-trouble-mrna\/\" target=\"_blank\" rel=\"noreferrer noopener\">Moderna<\/a> lopetti ALC-0315:n k\u00e4yt\u00f6n maksan yhteensopimattomuuden vuoksi ja kehitti itse SM-alustan (ALC-0315 oli osoittautunut liian myrkylliseksi Crigler-Najjarin syndrooman maksasairauden geeniterapiaan, joten silloinen tutkimuskumppani <em>Alexion<\/em> keskeytti tutkimuksen turvallisuussyist\u00e4), BioNTech\/Pfizer jatkaa niiden k\u00e4ytt\u00f6\u00e4 vastoin parempaa tietoaan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Der_Weg_in_die_Leber_und_die_Lange_der_Kette\"><\/span>Polku maksaan ja ketjun pituus<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><\/p>\n\n\n\n<p>... jatkuu ...<\/p>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Lukuaika<\/span> <span class=\"rt-time\"> 2<\/span> <span class=\"rt-label rt-postfix\">minuuttia<\/span><\/span>Mit\u00e4 lyhyempi PEG-ketju (polyetyleeniglykoli) on, sit\u00e4 myrkyllisempi LNP on. BioNTech selitt\u00e4\u00e4 t\u00e4m\u00e4n julkaisussaan \"Non-Immunotherapy Application of LNP-mRNA: Maximising Efficacy and Safety\", 10.05.2021, joskin hieman eri tavalla muotoiltuna: \"Maximising Efficacy.\" Toksisuus perustuu siihen, ett\u00e4 kaikki kolme ionisoituvaa kationista lipidi\u00e4 eiv\u00e4t ole biologisesti hajoavia ja niiden toksisuus on siksi...&nbsp;<a href=\"https:\/\/csiag.de\/fi\/blog\/2025\/06\/02\/toxizitaet-der-lnp-in-abhaengigkeit-der-laenge-der-peg-kette\/\" rel=\"bookmark\">Lue lis\u00e4\u00e4 \"<span class=\"screen-reader-text\">LNP:n myrkyllisyys PEG-ketjun pituudesta riippuen<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[628,316,1078],"tags":[5067,5066,5074,22,36,5080,5079,5069,5075,5071,4812,105,5073,5077,5070,5072,23,5076,5078,44],"class_list":["post-10036","post","type-post","status-publish","format-standard","hentry","category-corona","category-corona-blog","category-medizin","tag-alc-159","tag-alc-315","tag-alnylam","tag-biontech","tag-bnt162b2","tag-cholesterol","tag-dlin-mc3-dma","tag-dmg-peg2000","tag-elasomeran","tag-ionisierbar","tag-lnp","tag-moderna","tag-patisiran","tag-peg-lipid","tag-peg2000-dmg","tag-pegyliert","tag-pfizer","tag-phosholipid","tag-sterol","tag-tozinameran"],"acf":[],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/posts\/10036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/comments?post=10036"}],"version-history":[{"count":0,"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/posts\/10036\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/media?parent=10036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/categories?post=10036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.de\/fi\/wp-json\/wp\/v2\/tags?post=10036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}